The Point of Care Diagnostics Market 2014-2024

The Point of Care Diagnostics Market Forecast 2014-2024

Future Prospects for Leading Companies

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

www.visiongain.com

Contents

1.1 The Point of Care (POC) Diagnostics Market Highlights

1.2 Chapter Outlines

1.2.1 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2.1 What are In Vitro Diagnostic (IVD) Tests?

2.2 Classifying In Vitro Diagnostics

2.2.1 FDA Classifications

2.2.2 IVD Classification in Australia

2.2.3 EDMA Classification

2.2.3.1 Clinical Chemistry: Not To Be Discounted

2.2.3.2 Immunochemistry

2.2.3.3 Haematology

2.2.3.4 Microbiology

2.2.3.5 Genetic Testing

2.2.3.6 Point Of Care Diagnostics: The Most Prominent Type

2.3 Diagnostics Regulation of the IVD and POC Market

2.3.1 FDA and CLIA Regulation of IVD and POC Tests

2.3.2 Regulation of IVD/POC Diagnostics in the EU: The EC (European Commission)

Classification

2.4 Regulation for In-Vitro Diagnostics and POC Diagnostics

1. Report Overview

2. Introduction to In-Vitro Diagnostics and POC Diagnostics

www.visiongain.com

Contents

2.4.1 Top Ten Challenges in Regulation for In-Vitro Diagnostics

2.4.2 Device Excise Tax: A Threat to the Diagnostics Manufacturers

2.5 Uses of Point of Care (POC) Diagnostics

2.6 Advantages and Disadvantages of POC Diagnostics

3.1 Scope of this Report

3.2 Point of Care Diagnostics in the IVD Market, 2013

3.3 The World Point of Care Diagnostics Market in 2013

3.3.1 Self Testing Constituted the Largest Segment in the POC Market by the Point of

Delivery

3.3.2 Point of Care Diagnostics Market Segmentation

3.4 The Global IVD Market: Sales Forecast, 2014-2024

3.4.1 Which Segments Will Drive the Global IVD Market in the Next 10 Years?

3.5 The Global Clinical Diagnostics Market Forecast, 2014-2024

3.6 The Global Point of Care Diagnostics Market: Sales Forecast 2014-2024

3.6.1 The Drive of Personalised Medicine

3.7 Market for POC Diagnostics Products: Leading Segments to 2024

3.7.1 Breakdown of the World Point of Care Diagnostics Main Submarkets: Changing Shares

2014-2024

3.7.2 Blood Glucose Testing Market Forecast 2014-2024

3.7.3 Infectious Diseases Testing Market Forecast 2014-2024

3.7.4 Rapid Coagulation Testing Market Forecast 2014-2024

3.7.5 Rapid Cardiac Marker Testing Market Forecast 2014-2024

3. The Point of Care Diagnostics Market, 2014-2024

www.visiongain.com

Contents

3.7.6 Cholesterol Testing Market Forecast 2014-2024

3.7.7 Pregnancy Testing Market Forecast 2014-2024

3.7.8 Other Segments Market Forecast 2014-2024

3.7.8.1 Cancer Diagnostics Will Be a Major Driver for This Segment

3.7.8.2 The Haematology Market Will Be Driven by Blood Gas Tests

3.7.8.3 A Recently Discovered Biomarker for Sepsis Can Set The Potential For A Future

Rapid Blood Test

3.8 Scope of the Point of Care Diagnostics Market

3.9 Which Point of Care Diagnostic Segment Holds the Greatest Potential?

3.9.1 The Point of Care Diagnostics Market: Drivers and Restraints 2014-2024

4.1 Regional Breakdown of the World IVD Market: Sales Forecast by Country 2014-2024

4.2 Regional Breakdown of the World Point of Care Diagnostics Market in 2013

4.3 The World POC Diagnostics Market: Regional Forecasts 2014-2024

4.4 How Will Regional Market Shares Change to 2024?

4.5 The US POC Diagnostics Market, 2013

4.5.1 The US Will Still Dominate the POC Diagnostics Market in 2024

4.5.2 The US POC Diagnostics Market Forecast 2014 - 2024

4.5.3 Healthcare Expending in the US

4.5.4 The US POC Diagnostics Market: Drivers and Restraints

4.6 The Leading European POC Diagnostics Markets: Sales Forecasts 2014-2024

4.6.1 Variation in the European POCT Markets, 2014-2024

4.6.2 The German POC Diagnostics Market Forecast, 2014-2024

4. Leading National Point of Care Diagnostics Markets 2014-2024

www.visiongain.com

Contents

4.6.3 The UK POC Diagnostics Market Forecast 2014-2024

4.6.4 The French POC Diagnostics Market Forecast 2014-2024

4.6.5 The Italian POC Diagnostics Market Forecast 2014-2024

4.6.6 The Spanish POC Diagnostics Market Forecast 2014-2024

4.6.7 The Netherlands POC Diagnostics Market Forecast 2014-2024

4.6.8 The Belgian POC Diagnostics Market Forecast 2014-2024

4.6.9 The Swiss POC Diagnostics Market Forecast 2014-2024

4.7 The Japanese POC Diagnostics Market Forecast 2014-2024

4.7.1 The Japanese POC Diagnostics Market Overview 2014-2024

4.8 The BRICK Nations POC Diagnostics Market

4.8.1 The BRICK Nations POC Diagnostics Market: Overview

4.8.2 How Will BRICK Market Shares Change to 2024?

4.8.3 The BRICK Nations POC Diagnostics Market Forecast 2014-2014

4.8.3.1 The Chinese POCT Market Overview: Advances in China Lead to Expansion of

the Market

4.8.3.1.1 The Chinese POC Diagnostics Market Forecast 2014-2024

4.8.3.2 The Indian POC Diagnostics Market Overview

4.8.3.2.1 The Indian POC Diagnostics Market Forecast 2014-2024

4.8.3.3 The South Korean POC Diagnostics Market Forecast 2014-2024

4.8.3.4 The Brazilian POC Diagnostics Market Forecast 2014-2024

4.8.3.5 The Russian POC Diagnostics Market Forecast 2014-2024

4.9 Rest of the World POC Diagnostics Markets Forecasts 2014-2024

4.9.1 Further Insights: Point of Care Diagnostics Approach for Developing Countries

www.visiongain.com

Contents

5.1 POC Blood Glucose Testing Market Overview

5.2 Global POC Blood Glucose Testing Market, 2013

5.3 POC Blood Glucose Testing Market Forecast 2014-2024

5.3.1 POC Blood Glucose Testing Market by Type of Meter

5.3.2 POC Blood Glucose Testing Market Segment by Components

5.3.2.1 POC Blood Glucose Testing Devices Currently Available in the Market, 2014

5.3.3 Leading Regional Markets in the POC Blood Glucose Testing Market, 2013

5.3.4 Leading Companies in the POC Blood Glucose Testing Market, 2014

5.3.4.1 Other Companies in the POC Blood Glucose Testing Market: Recent Advances

5.3.5 Market Prospects to 2024: Which Product Will Lead the Market?

5.3.5.1 Advantages and Disadvantages of the Current CGM Tests in the Market

5.4 Drivers and Restraints for the POC Blood Glucose Testing Market, 2014-2024

6.1 Global POC Coagulation Testing Market: Overview

6.2 Global POC Coagulation Testing Market in 2013

6.2.1 PT/INR Monitoring is the Largest Segment in the POC Coagulation Testing Market

6.3 Products Available in the POC Coagulation Testing Market, 2014

6.3.1 Patient Self Testing is a Fastest Growing Segment

6.4 POC Coagulation Testing Market Segment by Components

6.4.1 Test Strips Generate 85% of the Sales in the PT/INR POC Testing Market

6.5 POC Coagulation Testing Market by Type of Drug

5. Global Blood Glucose Testing Market, 2014-2024

6. Global Coagulation Testing Market, 2014-2024

www.visiongain.com

Contents

6.5.1 Anticoagulants

6.5.2 Heparins

6.5.3 Vitamin K Antagonists

6.5.4 Direct Thrombin Inhibitors

6.5.5 Direct Factor Xa Inhibitors

6.6 The POC Coagulation Testing Market by Regions, 2013

6.7 POC Coagulation Testing Market Forecast 2014-2024

6.8 Leading Companies in the POC Coagulation Testing Market, 2014

6.8.1 Roche Dominated the POC Coagulation Testing Market with CoaguChek XS System in

2013

6.8.2 Market Prospects to 2024: Who Will Be The Leading Product?

6.9 Drivers and Restraints for the POC Coagulation Testing Market, 2014-2024

7.1 Cardiac Marker Diagnostic Testing Market: Overview

7.1.1 The Majority of Cardiac Marker Testing is Conducted in Critical Care Settings

7.2 The Global Cardiac Marker Diagnostic Testing Market 2013

7.3 Cardiac Marker Diagnostic Testing Market Forecast 2014-2024

7.3.1 Leading Regional Markets in the Cardiac Marker Diagnostic Testing, 2013

7.3.1.1 Global Deaths Due to CVD in High, Middle and Low Income Countries, 2014

7.3.2 Leading Companies in the Cardiac Marker Diagnostic Testing Market, 2014

7.3.3 Cardiac Marker Diagnostic Tests Currently Under Development, 2014

7.3.3.1 cobas h232 Cardiac Marker (Roche)

7.3.3.2 QL Care Analyzer (CardioGenics)

7. Global Cardiac Marker Testing Market, 2014-2024

www.visiongain.com

Contents

7.3.3.3 Handheld Device (bioMerieux/Royal Philips Electronics)

7.3.4 Cardiac Marker Diagnostic Testing Market: Leading Products

7.3.5 Which Company is Dominating the Market?

7.3.6 A Leading Product: Abbott’s i-STAT

7.4 Drivers and Restraints for the Cardiac Marker Diagnostic Testing Market, 2014-2024

7.4.1 Challenges for the New Entrants in the Cardiac Markers Diagnostic Testing Market

8.1 POC Infectious Diseases Testing Market: Overview

8.2 Global POC Infectious Diseases Testing Market, 2013

8.2.1 Breakdown of the POC Infectious Diseases Testing Market by Diseases, 2013

8.2.1.1 Influenza/Flu

8.2.1.2 HIV

8.2.1.3 Hepatitis

8.2.1.4 Tuberculosis

8.2.1.5 Sexually Transmitted Diseases

8.3 The POC Infectious Diseases Testing Market: Leading Products 2014

8.3.1 HIV Leading POC Diagnostics Products, 2014

8.3.1.1 HIV Diagnostics Kits Approved by the FDA, 2014

8.3.2 The HIV Rapid Testing Market in the US, 2014

8.3.3 HIV POC Tests Pipeline, 2014

8.3.4 Driving Factors for Growth of HIV Rapid Testing: Past and Future

8.4 The Hepatitis POC Testing Market

8.4.1 First Rapid HCV Test Approved in the US

8. Global Infectious Diseases Testing Market, 2014-2024

www.visiongain.com

Contents

8.4.2 The Influenza POC Testing Market and Leading Companies, 2014

8.4.3 Driving Factors for Growth of Hepatitis Rapid Testing

8.4.4 POC Infectious Diseases Recent Trends

8.4.4.1 OraQuick Marker, OraSure Technologies: First OTC Home-Use Rapid HIV Test

Approved by the FDA

8.4.4.2 Determine HIV-1/2 Ag/Ab Combo Test, Alere: First Rapid Diagnostic Test to

Detect Both HIV-1 Antigen And HIV-1/2 Antibodies

8.4.5 Leading Regional Markets in the POC Infectious Diseases Testing

8.4.5.1 Infectious Diseases POC Testing: Regional Markets in 2013

8.5 Infectious Diseases POC Testing Market: Leading Companies 2014

8.6 The POC Infectious Diseases Testing Market Forecast, 2014-2024

8.7 Drivers and Restraints for the POC Infectious Diseases Testing Market, 2014-2024

9.1 The POC Pregnancy Testing Market: Overview

9.2 Global POC Pregnancy Testing Market, 2013

9.3 The POC Pregnancy Testing Market Forecast 2014-2024

9.3.1 The POC Pregnancy Testing Market: Leading Products 2014

9.3.2 Leading Companies in the POC Pregnancy Testing Market, 2014

9.4 Drivers and Restraints for the POC Pregnancy Testing Market, 2014-2024

10.1 Global POC Cholesterol Testing Market: Overview

10.2 The Global POC Cholesterol Testing Market in 2013

9. Global Pregnancy Testing Market, 2014-2024

10. Global Cholesterol Testing Market, 2014-2024

www.visiongain.com

Contents

10.3 The POC Cholesterol Testing Market Forecast 2014-2024

10.3.1 POC Cholesterol Testing Biomarkers: Overview

10.3.2 The POC Cholesterol Testing Market by Components

10.3.3 Recent Developments in the POC Cholesterol Testing Market, 2014

10.3.3.1 New Product 2014: Roche’s Accutrend Plus

10.3.4 POC Cholesterol Testing Market: Considerations in Production

10.4 Drivers and Restraints for the POC Cholesterol Testing Market, 2014-2024

11.1 Leadng POC Diagnostics Companies in 2014

11.2 Roche: Overview

11.2.1 Roche: Global Presence

11.2.2 Roche Diagnostics, 2014-2024

11.2.2.1 Roche Business Performance within the IVD Market, 2013

11.2.2.2 Roche Diagnostics Market Forecast 2014-2024

11.2.3 Roche Diagnostics: Key Launches Planned for 2014

11.2.4 Roche Diagnostics: POC Product Portfolio

11.2.5 Roche: Recent M&A Activity and Strategic Collaborations

11.3 Abbott: Continuously Transforming to Meet the Changing Needs

11.3.1 Abbott: Market Leader in the Coronary DES Sector

11.3.2 Abbott Diagnostics: Overview, 2013

11.3.2.1 Abbott Diagnostics: Leading Point-of-Care Platform

11.3.3 Abbott’s Fast Growing Diagnostics Division: Sales Forecast 2014-2024

11.3.4 Abbott Portfolio Sales and Recent Performance Analysis

11. Leading Companies in the POC Diagnostics Market, 2014

www.visiongain.com

Contents

11.3.5 Abbott: The i-STAT System

11.3.5.1 Recent M&A Activity and Strategic Collaborations

11.3.5.1.1 Abbott Laboratories Agreed to Acquire IDEV Technologies

11.3.5.1.2 Collaboration with Merck

11.3.5.2 Abbott IVD Segment: Strengths & Challenges

11.4 Siemens: A Highly Diversified Company

11.4.1 Siemens Healthcare: Prospects within the IVD Market

11.4.2 Siemens Healthcare: Sales Forecast 2014-2024

11.4.3 Siemens Healthcare: POC Diagnostics Product Portfolio

11.4.3.1 Siemens Healthcare Diagnostics Recent Trends, 2014

11.4.3.2 Recent M&A Activity and Strategic Collaborations

11.5 Alere Inc: A Strong Player

11.5.1 Alere Inc Performance Analysis in 2013

11.5.2 Alere Inc: Performance in Geographic Markets in 2013

11.5.3 Alere Inc.: Product Profile Overview

11.5.4 Alere’s Professional Diagnostics Market in 2013

11.5.5 Product Profile Recent Trends, 2014

11.5.6 Alere Market Forecast 2014-2024

11.5.7 Alere: Recent M&A Activity and Strategic Collaborations

11.6 Other Companies of Interest: Recent M&A Activity and Strategic Collaborations, 2014

12.1 Introduction

12.2 Drivers and Restraints for the POC Diagnostics Market

12. Qualitative Analysis of the POC Diagnostics Market, 2014-2024

www.visiongain.com

Contents

12.2.1 Commercial Drivers

12.2.2 Commercial Restraints

12.3 Strategic Review of the POC Diagnostics Market

12.4 Pestel Analysis

12.4.1 Political Factors

12.4.2 Economic Factors

12.4.3 Socio-Cultural Factors

12.4.4 Technological Factors

12.4.5 Environmental Factors

12.4.6 Legal Factors

12.5 P5F Analysis

12.5.1 Competitive Rivalry

12.5.2 Rivalry Among Competitors: [High] Diagnostics is a Promising Market

12.5.3 Potential Entrants into the POC Diagnostics Market

12.5.3.1 Threat of New Entrants: [Medium] Continuous Arousal of Innovations in the

POCT Market

12.5.4 Who Are The Latent Substitutes?

12.5.5 Threat of Substitutes: [Medium]New Technologies Might Limit the Need to Monitor

Diseases

12.5.6 Vertical Integration With Suppliers and Buyers

12.5.6.1 Power of Suppliers: [Medium] Increased Competition Outweigh Suppliers

12.5.6.2 Power of Buyers: [High] Demand and Health Systems Will Go Hand by Hand

12.6 SWOT Analysis and Strategies

12.6.1 Strengths: Timing is First

www.visiongain.com

Contents

12.6.2 Weaknesses: Awaiting Expanded Reimbursement Options

12.6.3 Opportunities: A Promising Market

12.6.4 Threats: Unmet Needs in the Low-Middle Income Countries

13.1 Interview with Dr. Terenzio Facchinetti, Director Business Development of UL Life and

Health, UL International GmbH, Germany.

13.1.1 Impact of Remote Access on the POCT Market

13.1.2 UL’s Life and Health Business Unit: A Global Independent Safety Science Company

13.1.3 The Importance of Standardization and Regulations for the POC Market

13.1.4 Recommendations for the Future of POC Diagnostics: What to Expect

13.2 Interview with Dr. Keith Batchelder, CEO and Founder of Genomic Healthcare Strategies

(GHS), USA.

13.2.1 Advantages of POC Diagnostics

13.2.2 Restraints of POC Diagnostics

13.2.3 About Genomic Healthcare Strategies

13.2.4 US has the Highest Potential for the POC Diagnostics Market

13.2.5 Remarkable Insights

13.3 Interview with Dr. David Huckle, President and CEO of Adams Business Associates (ABA),

UK.

13.3.1 Remarkable Understanding on the POC Diagnostics Market

13.3.2 The Expert’s Perspective: Drivers and Restraints for POC Diagnostics

13.3.3 Recommendations for the Future POC Diagnostics Market

13.3.4 Further Insights from Dr. Huckle: Leading Companies

13. Expert Opinions

www.visiongain.com

Contents

13.4 Interview with Dr. Stéphan Cohen-Bacrie, Co-director of the Multi-site Laboratory of

Immunohematology and Immunogenetics, French Blood Establishment, Burgundy-

FrancheComté, France.

13.4.1 The French POC Diagnostics Market: Experienced Perspective

13.4.2 Restraints in the POC Diagnostics Market

13.4.3 The Advantage of Molecular Diagnostics

13.4.4 Innovations in Rural Africa: POC-labs

13.4.5 R&D in Focus: The Syndromic Panels and Microfluidics-based Methods

13.4.6 Where is the POC Diagnostics Market Heading?: An Expert’s View

14.1 Overview

14.2 The POC Testing in the IVD Market

14.3 The World POC Diagnostics Market Forecast 2014-2024

14.3.1 Leading Regional Markets Forecast 2014-2024

14.4 The World POC Diagnostics Market Forecast 2014-2024

14.5 POC Diagnostic Segments: Positions in the Market 2014

14.5.1 Current Advantages in POC Diagnostics

14.5.1.1 Comparison with Laboratory Testing

14.5.2 Leading POC Diagnostics Companies, 2014

14.6 Commercial Drivers for the Adoption of POC Tests

14.6.1 Commercial Restraints in the POC Diagnostics Market

14.7 Challenges for POC Diagnostics

14.8 The Future of the POC Diagnostics and Concluding Remarks

14. Conclusions

www.visiongain.com Page 114

The Point of Care Diagnostics Market Forecast 2014-2024: Future Prospects for Leading Companies

diagnostics market. Furthermore international private hospitals and lab chains are acquiring private

Belgian laboratories.

Table 4.13 The Belgian POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Belgium ($bn) 0.15 0.15 0.16 0.17 0.17 0.18 0.19 0.20 0.21 0.22 0.24 0.25

AGR (%) 4.5 4.6 4.7 4.8 4.9 5.1 5.2 5.3 5.4 5.4 5.5

CAGR (%) 2013-2018

CAGR (%) 2013-2024

4.7 2018-2024 5.3

5.0

Figure 4.15 The Belgian POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024

Source: Visiongain 2014

4.6.9 The Swiss POC Diagnostics Market Forecast 2014-2024

The Swiss POC diagnostics market is estimated to grow from $0.14bn in 2013 to $0.18bn in 2018,

representing a CAGR of 4.1%. Growth between 2018 and 2024 is expected to exhibit a CAGR of

0

1

2

3

4

5

6

7

8

0.00

0.05

0.10

0.15

0.20

0.25

0.30

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AGR

(%)

Sale

s $b

n

Year

Belgium ($bn) AGR (%)

Source: Visiongain2014



Table 5.5 Retail Prices of the Blood Glucose Meters and Strips Currently Available in the Market, by Company, 2014

Company Meter Manufacturer's Suggested Retail PriceFreeStyle Freedom Lite Meter: $19.99 Strips: $1.46-$1.52/stripFreeStyle InsuLinx Meter: $49.99 Strips: $1.54-$1.60/stripFreeStyle Lite Meter: $19.99 Strips: $1.46-$1.52/stripPrecision Xtra Meter: $19.99 Strips: $1.46-$1.52/strip

Glucocard 01Meter: Manufacturer declined to provide price Strips: Manufacturer declined to provide price

Glucocard 01-miniMeter: Manufacturer declined to provide price Strips: Manufacturer declined to provide price

Glucocard ExpressionMeter: Manufacturer declined to provide price Strips: Manufacturer declined to provide price

Glucocard VitalMeter: Manufacturer declined to provide price Strips: Manufacturer declined to provide price

WaveSense Presto Meter: $34.99 Strips: 37¢/stripWaveSense PrestoPro Meter: $38.83 Strips: 37¢/stripBreeze2 Meter: $24.99 Strips: $1.04/stripContour Meter: $19.99 Strips: $1.24/stripContour Next Meter: $19.99 Strips: 83¢/stripContour Next EZ Meter: $19.99 Strips: 83¢/stripContour Next Link Meter: Sold only w ith pump Strips: 83¢/stripContour Next USB Meter: $29.99 Strips: 83¢/stripRightest GE100 Meter: $14.99 Strips: 72¢/stripRightest GM100 Meter: $9.99-$12.99 Strips: 34¢-50¢/stripRightest GM300 Meter: $7.99-$10.99 Strips: 26¢-30¢/stripRightest GM550 Meter: $11.99-$14.99 Strips: 32¢-50¢/strip

BioSense Medical

Solus V2 Meter: $19.99 Strips: 40¢/strip

CVS Blood Glucose Monitor Featuring Truetrack Smart System

Meter: $14.99 Strips: 53¢/strip

CVS True2go Glucose Test Meter Meter: $9.99 Strips: 70¢/stripCVS Trueresult Blood Glucose Meter: $17.99 Strips: 70¢/strip

Diabetic Supply of Suncoast

Advocate Redi-Code PlusSpeaking Meter

Meter: $29.99 Strips: 50¢/strip

Entra Health Systems

MyGlucoHealth Wireless Meter: $89.95 Strips: 99¢/strip

Fifty50 2.0 Meter: $39.95 Strips: 74¢/strip

Fifty50 2.0 Sport Meter: $39.95 Strips: 74¢/strip

Fora D10 Meter: $79.99 Strips: 80¢/stripFora D20 Meter: $99.99 Strips: 80¢/stripFora D30e/f Meter: $149.99 Strips: 80¢/stripFora D40a/b Meter: $159.99/$199.99 Strips: 80¢/stripFora G30 Meter: $39.99 Strips: 80¢/stripFora G31a/b Meter: $84.99/$124.99 Strips: 80¢/stripFora GD20 Meter: $34.99 Strips: 80¢/stripFora GD40a/b Meter: $69.99 Strips: 80¢/stripFora Premium V10 Meter: $49.99 Strips: 80¢/stripFora V12 Meter: $79.99 Strips: $1.60/stripFora V30 Meter: $49.99 Strips: 80¢/stripTest N’ Go Meter: $149.99 Strips: $1.20/strip

Genesis Health

TechnologiesGenesis Meter Meter: $99.95 Strips: $1.08/strip

Bionime

Abbott Diabetes

Care

Arkray

AgaMatrix

Bayer

CVS/ Pharmacy

Fora Care

Fifty50 Medical

Source: Diabetes Forecast 2014; Visiongain 2014



Figure 11.8 Siemens Healthcare Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024

Source: Visiongain 2014

The outlook in terms of revenue looks promising for Siemens Healthcare in the near future. The

“Agenda 2013” initiative set up to increase its regional presence and competitiveness by improving

the cost position of the company’s Diagnostics business looks set to streamline its production

costs; leading to higher profits. Although Siemens Healthcare’s Diagnostics profit for fiscal 2013

was impacted by an increase in valuation allowances for receivables triggered by a debt rating

downgrade related to Greece, the diagnostics sector of the business will see year on year increase

in profits from 2014, Visiongain believes.

11.4.3 Siemens Healthcare: POC Diagnostics Product Portfolio

Siemens healthcare can be divided in: Healthcare IT & Infrastructure, Hearing Instruments,

Laboratory Diagnostics, Medical Imaging and Therapy Systems.

Siemens Healthcare Diagnostics provides point-of-care products and services that enable

healthcare providers to render better patient management and help ensure optimized clinical

outcomes.

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

0

5

10

15

20

25

30

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AGR

(%)

Sale

s $b

n

Year

Siemens Revenue ($bn) AGR (%)

The Point of Care Diagnostics Market 2014-2024

Business

Transcript of The Point of Care Diagnostics Market 2014-2024